Cameron D J
Jpn J Exp Med. 1983 Feb;53(1):19-26.
It has been previously reported that human peripheral blood monocyte derived macrophages acquire enhanced cytotoxicity for tumor cells after incubation in either lymphocyte mediators or lipopolysaccharide. When the macrophages obtained from renal transplant recipients were studied we observed that the macrophages obtained from 1 to 4 year post-transplant survivors were cytotoxic for tumor cells whereas, macrophages obtained from renal transplant recipients at 10 days to 7 months post-transplantation have a depressed capacity to kill human tumor cells in vitro. Furthermore, in a long term study, eight renal patients were tested repeatedly up to 1 year post-transplant. All 5 renal transplant recipients showing no clinical evidence of rejection during this 1 year study were found to possess macrophages which were non-cytolytic for tumor cells whereas 2 of the 3 patients undergoing rejection crises did possess cytotoxic macrophages. Thus, it appears that at times of rejection crises, these patients' macrophages are converted into cytolytic cells.
先前有报道称，人类外周血单核细胞衍生的巨噬细胞在淋巴细胞介质或脂多糖中孵育后，对肿瘤细胞的细胞毒性增强。当研究肾移植受者获得的巨噬细胞时，我们观察到，移植后1至4年存活者获得的巨噬细胞对肿瘤细胞具有细胞毒性，而移植后10天至7个月的肾移植受者获得的巨噬细胞在体外杀伤人类肿瘤细胞的能力则有所下降。此外，在一项长期研究中，对8名肾病患者进行了长达移植后1年的反复检测。在这1年研究期间，所有5名无排斥反应临床证据的肾移植受者被发现其巨噬细胞对肿瘤细胞无细胞溶解作用，而3名经历排斥危机的患者中有2名确实拥有细胞毒性巨噬细胞。因此，似乎在排斥危机时期，这些患者的巨噬细胞会转化为溶细胞性细胞。
